Hormone-refractory prostate cancer responding to capecitabine - 26/08/11
Abstract |
A 66-year-old male patient with advanced prostate cancer presented with bony metastases, including pathologic fractures and hepatosplenomegaly. The patient responded to luteinizing hormone-releasing hormone agonists for more than 1 year. A clear progression while taking luteinizing hormone-releasing hormone agonists manifested as a progressive rise in prostate-specific antigen, alkaline phosphatase, hepatosplenomegaly, and myelophthisic pancytopenia. We administered capecitabine for 5 months with a complete clinical response. At last follow-up, the patient’s liver function tests and prostate-specific antigen level have normalized. Liver size by computed tomography and blood counts both improved. To our knowledge, no previous case reports of capecitabine in the treatment of prostate cancer have been published.
Le texte complet de cet article est disponible en PDF.Plan
Vol 61 - N° 2
P. 462 - février 2003 Retour au numéro
Article précédent
- Multilocular cystic renal cell carcinoma with osseous metaplasia in a 25-year-old woman
- Tammy L Bloom, Christine L Gray Sears, Todd R Williams, Ron L Linfesty, Christopher L Amling
- Lateral gluteal myonecrosis in a patient undergoing partial nephrectomy in the modified flank position
- James A Brown
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?